Cerebrolysin in acute ischemic stroke


Phase N/A Results


A significant improvement of motor function (PHA scale) was demonstrated for Cerebrolysin patients compared to placebo patients on days 10 and 20, after the end of treatment (p<0.001). This difference was partly maintained until the follow-up visit. The GNS total score as well as all subscores showed a trend in favor of Cerebrolysin after the end of treatment. No significant differences were observed in the BI.